Risk of Radiation Necrosis With Concurrent vs Nonconcurrent Administration of ICIs and Single-Fraction SRS for NSCLC, Melanoma, and RCC Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients
Int. J. Radiat. Oncol. Biol. Phys 2023 Jan 20;[EPub Ahead of Print], EJ Lehrer, RO Kowalchuk, J Gurewitz, K Bernstein, D Kondziolka, A Niranjan, Z Wei, LD Lunsford, KR Fakhoury, CG Rusthoven, D Mathieu, C Trudel, TD Malouff, H Ruiz-Garcia, P Bonney, L Hwang, C Yu, G Zada, S Patel, CP Deibert, P Picozzi, A Franzini, L Attuati, RN Prasad, RR Raval, JD Palmer, CC Lee, HC Yang, WS Harmsen, BM Jones, S Sharma, MS Ahluwalia, JP Sheehan, DM TrifilettiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.